Carlsmed (CARL) Receivables (2024 - 2026)

Carlsmed (CARL) has reported Receivables for 3 consecutive years, with $13.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Receivables rose 41.85% year-over-year to $13.8 million; the trailing twelve-month figure through Jun 2026 stood at $13.8 million (up 41.85% YoY), and the FY2025 full-year result was $11.4 million, up 67.93% from the prior year.
• Receivables advanced to $13.8 million in Q2 2026 per CARL's latest filing, from $12.3 million in the prior quarter.
• Across five years, Receivables topped out at $13.8 million in Q2 2026 and bottomed at $6.8 million in Q4 2024.
• Historically, Receivables has averaged $10.9 million across 3 years, with a median of $11.3 million in 2025.
• The sharpest annual moves came in 2025 and 2026: Receivables surged 67.93% in 2025, then jumped 41.85% in 2026.
• Over 3 years, Receivables stood at $6.8 million in 2024, then surged by 67.93% to $11.4 million in 2025, then gained by 21.24% to $13.8 million in 2026.
• According to Business Quant data, Receivables over the past three periods registered $13.8 million, $12.3 million, and $11.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.